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Abstract
Gremlin-1, a bone morphogenetic protein (BMP) antagonist, is overexpressed in various cancerous tissues but its role in
carcinogenesis has not been established. Here, we report that gremlin-1 binds various cancer cell lines and this interaction is
inhibited by our newly developed gremlin-1 antibody, GRE1. Gremlin-1 binding to cancer cells was unaffected by the
presence of BMP-2, BMP-4, and BMP-7. In addition, the binding was independent of vascular endothelial growth factor
receptor-2 (VEGFR2) expression on the cell surface. Addition of gremlin-1 to A549 cells induced a fibroblast-like morphology
and decreased E-cadherin expression. In a scratch wound healing assay, A549 cells incubated with gremlin-1 or transfected
with gremlin-1 showed increased migration, which was inhibited in the presence of the GRE1 antibody. Gremlin-1
transfected A549 cells also exhibited increased invasiveness as well as an increased growth rate. These effects were also
inhibited by the addition of the GRE1 antibody. In conclusion, this study demonstrates that gremlin-1 directly interacts with
cancer cells in a BMP- and VEGFR2-independent manner and can induce cell migration, invasion, and proliferation.
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Introduction
Gremlin-1 is a 20.7-kDa protein consisting of 184 amino acids
with a cysteine-rich region, a cysteine knot motif, and a structure
shared by members of the TGF-b superfamily. This protein is
evolutionarily conserved and the human gremlin gene (GREM1)
has been mapped to chromosome 15q13-q15 [1,2]. Gremlin-1 is a
secreted protein and three isoforms have been reported [3].
Isoform 1 is the most common isoform and isoforms 2 and 3 have
deletions of amino acids 39–79 and 10–79, respectively. Gremlin-1
forms heterodimers with BMP-2, BMP-4, and BMP-7 and thus
inhibits their binding to receptors on the cell surface [4–6]. In
addition, Gremlin-1 plays an important role in regulating BMPs
during lung, limb, and kidney development as well as during
neural crest cell differentiation [7,8]. In addition to its antagonistic
effect on soluble ligands, gremlin-1 interacts intracellularly with
the BMP-4 precursor protein and downregulates BMP-4-mediated
signaling activity in embryonic lungs [9]. Gremlin-1 also interacts
with Slit proteins, a family of secreted axonal guidance proteins,
and acts as an inhibitor of monocyte chemotaxis [10]. Recently it
was reported that gremlin-1 binds vascular endothelial growth
factor receptor-2 (VEGFR2) in a BMP-independent manner and
modulates angiogenesis [11]. Gremlin-1 is overexpressed in
various human tumors including carcinomas of the cervix,
endometrium, lung, ovary, kidney, breast, colon, and pancreas
[12,13] but its role in carcinogenesis has not been studied in detail.
In this study, we report that gremlin-1 directly binds to the
cancer cell lines A549, HeLa, A172, and A431. In A549 cells,
gremlin-1 induces cell migration, proliferation, and invasion. The
interaction with cancer cells was not mediated by VEGFR2, the
only known cell surface receptor of gremlin-1, and was unaffected
by the presence of BMPs. Gremlin-1-transfected A549 cells
showed increased tumor growth in vivo, suggesting that gremlin-1
overexpression may play a role in tumorigenesis.
Materials and Methods
Cell culture
A549, HeLa, A172, and A431 cells were obtained from the
Korean Cell Line Bank (Seoul, Republic of Korea) and human
umbilical vein endothelial cells (HUVECs) were obtained from
Invitrogen (Carlsbad, CA). A549, A172 and A431 cells were
grown in RPMI-1640 media (Welgene, Seoul, Korea) supple-
mented with 10% FBS (GIBCO, Grand Island, NY). HeLa cells
were cultured in MEM media (Welgene) supplemented with 10%
FBS. HUVECs were cultured in endothelial cell growth media-2
(EGM-2, Lonza, Walkersville, MD).
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A549 cells (5.0610
5 cells) were plated 1 day prior to transfection
to achieve 70% confluency at the time of transfection. The gremlin
cDNA was amplified from a human cervical tissue cDNA library
as described previously [12]. HindIII and XhoI restriction sites were
introduced at the 59 and 39 ends, respectively, using the following
PCR primers: 59 CCC AAG CTT ATG AGC CGC ACA GCC
TAC AC 39 and 59 CCG CTC GAG ATC CAA ATC GAT GGA
TAT GC 39. The PCR product was digested with HindIII and
XhoI and then ligated into the pcDNA3.1/myc-His vector
(Invitrogen). This expression vector was transfected into cells
using the Lipofectamine 2000 reagent (Invitrogen) according to
the manufacturer’s instructions. To transfect a 100 mm dish of
A549 cells, 24 mg of plasmid was mixed with 60 mlo f
Lipofectamine. Antibiotic selection was performed using 1.0 mg/
ml of G418 (Invitrogen). The selected cells are termed gremlin-1-
A549 cells. In a parallel experiment, A549 cells were transfected
with pcDNA3.1/myc-His vector alone and used as mock-A549
cells.
Expression and purification of gremlin-1
Gene encoding human gremlin-1 and human IgG1-Fc fusion
protein was constructed using overlapping PCR as described
previously [15]. The linker primer sequences (forward and
backward for gremlin-1) are as follows; 59 GGC CCC ACC
GGC CCC ATC CAA ATC GAT 39, and 59 GGG GCC GGT
GGG GCC TCG GGT GGC GGT GGC 39. The linker primer
sequences forward and backward for human IgG1-Fc are as
follows; 59 AAG CTT GTG GCC CAG GCG GCC ATG AGC
CGC ACA GCC TAC 39, and 59 GGA TCC TCA TTT TGG
CGG GGA CAG GGA GAG 39. The PCR products were
digested with HindIII and BamHI and cloned into the pCEP4
expression vector (Invitrogen). HEK293F cells (Invitrogen) were
cultured in GIBCO FreeStyle
TM 293 Expression media (Invitro-
gen) at a cell density between 0.1610
6 and 2.0610
6 cells/ml. Cells
were grown in disposable Erlenmeyer tissue culture flasks with
vented caps (Corning Inc.) at 135 rpm on an orbital shaking
incubator (37uC, 8% CO2, Minitron, INFORS HT, Switzerland).
One day prior to transfection, cell cultures were diluted with fresh
media to achieve a density of 1.0610
6 cells/ml, which resulted in a
density of 2.0610
6 cells/ml on the day of transfection. HEK293F
cells were transfected with pCEP4 expression vector using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Transfected cells were again cultured in the orbital
shaking incubator and culture supernatants were harvested the
third day after transfection. The gremlin-1-Fc fusion protein was
purified using protein A affinity gel chromatography as described
previously [15].
Generation of gremlin-1 antibody (GRE1)
New Zealand white rabbits were immunized with gremlin-1-Fc
and a rabbit immune library was constructed using total RNA
prepared from the bone marrow and spleen of the immunized
rabbits, as described previously [14]. Single-chain variable
fragment (scFv) clones were selected from the library using phage
display as described previously [15]. The scFv fragments were
converted to full length IgG and overexpressed as described
previously [16]. The specificity of the GRE1 antibody was
determined using western blot analyses (Fig. S1).
RNA isolation and RT-PCR
Total RNA was isolated from A549 cells, HeLa cells, and
HUVECs using the TRIzol reagent (Invitrogen) according to the
manufacturer’s instructions. cDNA was synthesized using the
SuperscriptH III First-Strand Synthesis system (Invitrogen).
The primer sequences were as follows: VEGFR-2 forward: 59-
TGATCGGAAATGACACTGGA-39, VEGFR-2 reverse: 59-
TGCTTCACAGAAGACCATGC-39, gremlin-1 forward: 59-AA-
CAGTCGCACCATCATCAA-39, gremlin-1 reverse: 59-
AATTTCTTGGGCTTGCAGAA-39, GAPDH forward: 59-
AGGTGAAGGTCGGAGTCAACG-39, GAPDH reverse: 59-
AGGGGTCATTGATGGCAACA-39. The PCR mixtures were
prepared according to the manufacturer’s instructions with PCR
conditions of 35 cycles of 30 sec at 94uC, 30 sec at 56uC, and
1 min at 72uC on a 2720 Thermal Cycler (Applied Biosystems,
Foster City, CA).
Flow cytometry
Adherent cells were trypsinized and washed with 1% (w/v) BSA
in phosphate-buffered saline (PBS). Suspension cells were collected
by centrifugation at 5006g for 2 min and washed with 1% (w/v)
BSA in PBS. All cells were incubated with His-tagged gremlin-1
(R&D Systems, Minneapolis, MN) at a final concentration of
100 nM in 1% (w/v) BSA in PBS for 1 h at 37uC. The cells were
then washed twice with 1% (w/v) BSA in PBS and incubated for
30 min at 37uC in the dark with a FITC-conjugated His antibody
(Abcam, Cambridge, UK) at a final concentration of 5 mg/ml.
Cells were then washed twice with 1% (w/v) BSA in PBS and
resuspended in 500 ml of PBS prior to analysis on a FACSCanto II
flow cytometer (BD Biosciences, San Jose, CA).
To determine the neutralizing efficacy of the gremlin-1 antibody
GRE1, cells were incubated with 100 nM of His-tagged gremlin-1
and 10 mM of GRE1 in 1% (w/v) BSA in PBS for 1 h at 37uC and
probed with a FITC-conjugated His antibody (Abcam).
A549 cells were treated with 1 mM of BMP-2, BMP-4, or BMP-
7 (R&D Systems, Minneapolis, MN) and 100 nM of gremlin-1-Fc
simultaneously and incubated for 1 h at 37uC. Cells were probed
with FITC-conjugated IgG-Fc specific antibody (5 mg/ml, Invi-
trogen). Cells were then analyzed on a FACSCanto II flow
cytometer.
Western blot analyses
HUVECs, A549 cells, and HeLa cells were lysed in ice-cold lysis
buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA,
1% Triton-X 100, 0.1% SDS, 1 mM PMSF] containing a
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO).
Western blots were performed as described previously [14]. E-
cadherin (1:1,000 dilution; Abcam), VEGFR-2 (1:1,000 dilution;
Cell Signaling Technology, Danvers, MA), and b-actin (1:10,000
dilution; Applied Biological Materials, Richmond, BC) antibodies
were used as the primary antibodies. The secondary antibodies
were horseradish peroxidase (HRP)-conjugated anti-mouse IgG
(1:1,000 dilution; Pierce Chemical Co., Rockford, IL) or HRP-
conjugated anti-rabbit IgG (1:1,000 dilution; Pierce Chemical
Co.). Blots were visualized using an enhanced chemiluminescence
system (Pierce) per the manufacturer’s instructions.
To analyze E-cadherin expression, A549 cells (1.0610
5 cells/
well) were seeded onto a 60-mm dish and grown to 50%
confluence. Cells were treated with 100 nM of His-tagged
gremlin-1 for 3 days. Cells were lysed and analyzed by western
blot as described above.
To determine the neutralizing efficacy of the gremlin-1 antibody
GRE1, gremlin-1-A549 cells and mock-A549 cells (1.0610
5 cells/
well) were seeded onto a 60-mm dish to 50% confluence. Mock-
A549 cells were cultured without treatment and Gremlin-1-A549
cells were cultured for 24 h in the presence of 10 mM GRE1 or
control antibody (Palivizumab, Synagis, Abbott Laboratories,
Tumor Cell Proliferation and Invasion by Gremlin-1
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described above.
To analyze gremlin-1 expression, the culture supernatants from
mock-A549 and gremlin-1-A549 cells were resolved by SDS-
PAGE as described above. The blots were incubated for 1 h at
room temperature with HRP-conjugated -His antibody (1:1000
dilution, R&D Systems). Blots were visualized using an enhanced
chemiluminescence system (Pierce) per the manufacturer’s in-
structions.
Enzyme immunoassay
Microtiter plates (Corning Costar Corp., Cambridge, MA) were
coated with 100 nM of BMP-2, BMP-4, or BMP-7 (R&D Systems)
and blocked with 1% (w/v) skim milk in PBS. Gremlin-1-Fc
(10 nM) or gremlin-1-Fc (10 nM) plus 500 nM of GRE1 antibody
were added to the wells. After washing, plates were incubated with
an HRP-conjugated IgG-Fc specific antibody (1:5,000 dilution;
Pierce Chemical Co.). 2,29-azino-bis(3-ethylbenzothiazoline-6-
sulphonic acid (ABTS) substrate solution (Amresco, Solon, OH)
was used for the coloring reaction as described previously [17].
Experiments were performed in triplicate.
Crystal violet staining assay
A549 cells were seeded in 24-well plates (1.0610
4 cells/well)
and treated with 100 nM of His-tagged gremlin-1 for 3 days.
Media was removed and cells were washed with PBS and fixed
with 4% paraformaldehyde in PBS for 10 min. Cells were stained
with 0.05% crystal violet in distilled water for 30 min. The staining
solution was removed and the cells were washed 3 times with PBS
as described [18]. Images were obtained using a Leica DFL290
camera (Leica Microsystems, Wetzlar, Germany) and analyzed
using Leica application suite software (Leica Microsystems)
Immunofluorescence staining
A549 cells (1.5610
4 cells/well) were seeded on glass coverslips
coated with poly-L-lysine (100 mg/ml, Sigma) and grown to 50%
confluence. Cells were treated with 100 nM of His-tagged
gremlin-1 for 3 days, rinsed in PBS, and fixed in 4%
paraformaldehyde in PBS for 30 min at room temperature. Fixed
cells were permeabilized with 0.2% Triton X-100 in PBS (PBST)
at room temperature for 10 min and then blocked with 1% gelatin
in PBST for 30 min at room temperature. Immunofluorescent
staining was performed using an E-cadherin antibody (Abcam)
followed by an Alexa 488-conjugated secondary antibody
(Invitrogen). Nuclei were stained with DAPI (1:1,000 dilution;
Invitrogen) and actin filaments were stained using rhodamine-
phalloidin (1:1,000 dilution; Invitrogen). Coverslips were mounted
on glass slides using aqueous mounting medium with anti-fading
agents (Biomeda Corp., Foster City, CA). Images were acquired
using a LSM 5 PASCAL Laser Scanning Microscope (Carl Zeiss,
Germany) and analyzed using LSM 5 PASCAL software.
Cell migration assay
Cells were seeded in 24-well plates at a density of 1.0610
5 cells
per well. A scratch wound was generated by scratching with a
pipette tip. After rinsing with media to remove detached cells,
100 nM of His-tagged gremlin-1 was added to the cultures for
24 h. Photographic images were taken from each well immediately
and again after 24 h using a Leica DFL290 camera (Leica
Microsystems). Images were analyzed using Leica application suite
software (Leica Microsystems). The distance that cells migrated
through the area created by scratching was determined by
measuring the wound width at 24 h and subtracting it from the
wound width at the start. The values obtained were then expressed
as % migration, setting the migrating distance of cells untreated as
100% as described [19].
To determine the neutralizing efficacy of the gremlin-1 antibody
GRE1, scratched cells were incubated for 24 h with His-tagged
gremlin-1 alone or plus 10 mM GRE1 (or 10 mM control
antibody). The distance was determined as described above.
Using the same protocol, mock transfected A549 cells and
gremlin-1 transfected A549 cells were seeded and scratched.
Mock-A549 cells were cultured without any treatment while
Gremlin-1-A549 cells were cultured for 24 h in the presence of
10 mM GRE1 or control antibody. The distance was determined
as described above. The results were representative of three
independent experiments.
Cell invasion assay
Cell invasion assays were performed using ECM coated inner
chambers (Chemicon, Temecula, CA) per the manufacturer’s
instructions. Mock-A549 cells and gremlin-1-A549 cells (3.0610
5
cells per well) were suspended in 300 ml of serum-free media.
Complete media (500 ml) containing 10% FBS was added to the
bottom wells of the plate. Cells were incubated for 48 h. Non-
migrating cells were wiped away and washed with PBS. The
membranes were fixed with 4% paraformaldehyde in PBS and
stained with a crystal violet stain solution (Chemicon). Images were
acquired using a Leica DFL290 camera (Leica Microsystems) and
analyzed using Leica application suite software. Migrated cells
were counted in four separated fields per well. The values obtained
were then expressed as % invasion, setting the cell counts of mock-
A549 cells as 100%. The results were representative of three
independent experiments.
Cell proliferation assay
Cell proliferation was determined using CellTiter 96 Aqueous
One Solution Cell Proliferation Assay (Promega, Madison, WI)
following the manufacturer’s protocol. Experiments were per-
formed in 96-well plates in RPMI-1640 media supplemented with
10% FBS. Mock-A549 cells and gremlin-1-A549 cells were seeded
at a density of 1,000 cells per well. After 24 h, cells were washed
twice with serum-free media and cultured in 100 ml of complete
media with or without 3 mM of GRE1 antibody. Cell proliferation
was determined by using Labsystems Multiskan Ascent Photomet-
ric plate reader (Thermo Labsystems, Franklin, MA) for a 96 well
plate with a 492 nm filter. Experiments were performed in
triplicate.
In vivo tumorigenesis
All animal experiments were authorized by the Institute of
Laboratory Animal Resources Seoul National University and Use
Committee (Permit number: SNU-11-0207). Gremlin-1-A549 cells
and mock-A549 cells (1.0610
6 cells/mouse) were injected
subcutaneously in the right flank of 4- to 6 week-old female,
athymic nude mice (7 mice in each treatment group). Tumor
formation and size were assessed weekly by caliper measurements
of the length and width of the tumors. Tumor volumes were
calculated using the following formula: (Length6Width6Height)/
2 [20].
Statistical analyses
Statistical significance was determined using a Student’s t-test
and P values,0.05 were considered statistically significant. All
statistical tests were performed using SPSS version 17.0 software
(SPSS, Chicago, IL).
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Gremlin-1 directly interacts with human cancer cell lines
The interaction of gremlin-1 with cancer cell lines was analyzed
by flow cytometry. Four cancer cell lines, including A549 cells,
interacted with gremlin-1 (Fig. 1). The gremlin-1 antibody GRE1
inhibited the binding of gremlin-1 to all cell lines, including A549
(Fig. 1). These data indicate that gremlin-1 directly interacts with
cancer cells depending on a motif either co-localized with the
epitope of antibody GRE1 or affected by the binding of GRE1.
Next, we evaluated whether the interaction of gremlin-1 with the
cell lines was mediated by VEGFR2, the only known cell surface
receptor of gremlin-1 [11]. In HUVECs, the binding of gremlin-1
was not significant (Fig. 2A) but VEGFR2 mRNA and protein
expression was confirmed using RT-PCR and immunoblot
analyses (Fig. 2B and 2C). However, although gremlin-1 interacted
with A549 and HeLa cells (Fig. 1), VEGFR2 mRNA and protein
were not detected in these cells as measured by RT-PCR and
immunoblot analyses (Fig. 2B and 2C). Therefore, we conclude
that gremlin-1 can interact with cancer cells directly and this
interaction does not have to be mediated by VEGFR2.
The most characterized function of gremlin-1 is as a BMP
antagonist. Therefore, we investigated the influence of BMPs on
the interaction of gremlin-1 with A549 cells. Gremlin-1 forms
heterodimers with BMP-2, BMP-4, and BMP-7 and interrupts the
binding of BMPs to their receptors. In an enzyme immunoassay,
gremlin-1 interacted with BMP-2 and BMP-4. Gremlin-1 did not
interact with BMP-7 in our experimental conditions and the
reason for this is unclear. Addition of the neutralizing antibody
GRE1 did not inhibit the interaction of gremlin-1 with BMP-2 or
BMP-4 (Fig. 3A, *P,0.05). In flow cytometric assays, the presence
of a molar excess of BMPs did not affect the interaction of gremlin-
1 with A549 cells (Fig. 3B). These results indicate that there are
likely two separate motifs in gremlin-1 that mediate its interaction
with A549 cells and BMPs, and these motifs do not co-localize.
Gremlin-1 induces A549 cell scattering and migration
When A549 cells were treated with gremlin-1 for 3 days, the cell
morphology became fibroblast-like and the cells became scattered
(Fig. 4A). E-cadherin expression was markedly reduced in A549
cells cultured with gremlin-1 as evaluated by immunoblot analysis
and immunofluorescence staining (Fig. 4B and 4C). In a scratch
wound healing assay, treatment with gremlin-1 for 24 h
significantly increased the migration of A549 cells (Fig. 4D,
***P,0.001). This effect was completely abolished upon addition
of the neutralizing antibody GRE1 (Fig. 4D, **P,0.01).
Characterization of gremlin-1 transfected A549 cell lines
Next, we generated stably transfected A549 cell lines containing
gremlin-1 (gremlin-1-A549) or empty vector (mock-A549). Using
RT-PCR and western blot analyses, we confirmed increased levels
of gremlin-1 transcript and protein in the gremlin-1-A549 cells
(Fig. 5A). E-cadherin expression was reduced in gremlin-1-A549
cells as compared with mock-A549 cells. However, its expression
slightly increased upon addition of the neutralizing antibody
GRE1 to the culture media (Fig. 5B). For cell invasion assays,
gremlin-1-A549 cells or mock-A549 cells were plated on the upper
surface of ECM coated membrane of inner chambers. After 48 h,
the cells that migrated through ECM and attached to the bottom
of the membrane were stained with crystal violet. We determined
that a higher number of gremlin-1-A549 cells migrated as
compared to mock-A549 cells (Fig. 5C, ***P,0.001). In a scratch
wound healing assay, gremlin-1-A549 cells also showed increased
migration as compared with mock-A549 cells, and migration was
Figure 1. Gremlin-1 interacts with human cancer cell lines. Cells were incubated with gremlin-1, in the presence or absence of the neutralizing
antibody GRE1 as described. The four cancer cell lines interacted directly with gremlin-1 and this interaction was inhibited upon the addition of the
neutralizing antibody GRE1.
doi:10.1371/journal.pone.0035100.g001
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GRE1 (Fig. 5D, **P,0.01, ***P,0.001). To identify whether
gremlin-1 influences cell growth, a cell proliferation assay was
performed. Gremlin-1-A549 cells had a higher growth rate
compared to mock-A549 cells or untransfected A549 cells
(Fig. 5E, *P,0.05). The increased growth rate of gremlin-1-
A549 cells was inhibited by the addition of the neutralizing
antibody GRE1 (Fig. 5E).
Gremlin-1 enhances tumor growth in vivo
To evaluate the effect of gremlin-1 on tumorigenesis, gremlin-1-
A549 cells or mock-A549 cells were injected subcutaneously into
nude mice. Tumor size was measured weekly using a digital
caliper. The tumor volume in mice injected with gremlin-1-A549
cells increased more rapidly than those injected with mock-A549
cells, with an approximately 500 mm
3 difference in tumor volume
at 14 weeks post injection (Fig. 5F, *P,0.05). This result suggests
that increased expression of gremlin-1 may play a role in
tumorigenesis.
Discussion
Gremlin-1 has a critical role regulating BMPs during embryonic
development but its expression is down-regulated in normal adult
tissues [7,8]. Differential display RT-PCR analysis revealed that
gremlin-1 is overexpressed in various human tumors including
carcinoma of the lung, ovary, kidney, breast, colon, pancreas, and
cervix [12]. It was also reported that gremlin-1 is overexpressed in
Figure 2. The interaction of gremlin-1 with cancer cells is
independent of VEGFR2 expression. (A) Gremlin-1 does not
interact with HUVECs as measured by flow cytometry. (B) RT-PCR
analysis of VEGFR2 mRNA indicates the presence of VEGFR2 in HUVECs
but not in A549 or HeLa cells. (C) Immunoblot analysis using a VEGFR2
antibody indicates that A549 and HeLa cells do not express VEGFR2.
doi:10.1371/journal.pone.0035100.g002
Figure 3. Addition of the neutralizing antibody GRE1 does not
interrupt the interaction between gremlin-1 and BMPs. (A)
Interaction of gremlin-1 with BMP-2, BMP-4, and BMP-7 as measured by
enzyme immunoassay. The neutralizing antibody GRE1 does not affect
the interaction between gremlin-1 and BMPs. *P,0.05, Student’s t test.
(B) The interaction of gremlin-1 with A549 cells is unaffected by
treatment with a 10 times molar excess of BMP-2, BMP-4, and BMP-7 as
measured by flow cytometry.
doi:10.1371/journal.pone.0035100.g003
Tumor Cell Proliferation and Invasion by Gremlin-1
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35100the stroma of basal cell carcinoma (BCC) but not in normal skin
according to immunohistochemical analysis. In in situ hybridiza-
tion analyses, elevated gremlin-1 mRNA levels were detected in
various cancer tissues, including esophagus, bladder, and prostate
[21]. However, the function of gremlin-1 in carcinogenesis has not
yet been elucidated.
In this study, we report that gremlin-1 interacts with various
cancer cell lines (Fig. 1). Recently it was reported that gremlin-1
interacts with VEGFR2 and induces angiogenic responses in vitro
and in vivo [11]. We evaluated whether VEGFR2 was responsible
for the interaction of gremlin-1 with cancer cells. We did not
detect VEGFR2 expression in A549 or HeLa cells though both
cell lines strongly interacted with gremlin-1 (Fig. 2). Therefore, we
conclude that gremlin-1 can bind cancer cells and this binding is
not mediated by VEGFR2.
Gremlin-1 is a BMP antagonist that specifically binds to and
inhibits the activity of BMP-2, BMP-4, and BMP-7 [4,5]. BMPs
are multi-functional growth factors known to play important roles
in morphogenesis and homeostasis of many tissues. In addition,
BMP-2, BMP-4, and BMP-7 are frequently overexpressed in
various cancers including breast and prostate [22–24]. It was
reported that BMP-4 reduced the proliferation of BCC cells and
Figure 4. Gremlin-1 induces the scattering and migration of A549 cells in vitro. (A) A549 cells appear fibroblast-like after incubation with
gremlin-1 for 3 days. (B) E-cadherin protein expression is reduced in A549 cells after incubation with gremlin-1 for 3 days. (C) E-cadherin
immunofluorescence (green) in A549 cells is reduced after incubation with gremlin-1 for 3 days. Nuclei were counterstained with DAPI (blue) and
actin filaments were counterstained with rhodamine-phalloidin (red). (D) Migration of A549 cells after incubation with gremlin-1 only or gremlin-1
plus GRE1. Addition of the neutralizing antibody GRE1 abolishes gremlin-1 induced migration. **P,0.01, ***P,0.001, Student’s t test.
doi:10.1371/journal.pone.0035100.g004
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4 indirectly [21]. We verified that the mRNA levels of BMP-2 and
BMP-4 were highly expressed in A549 cells (data not shown). We
also evaluated the interaction of gremlin-1 with A549 cells in the
presence of BMP-2, BMP-4, or BMP-7. We determined that
gremlin-1 strongly bound BMP-2 and BMP-4 (Fig. 3A) but this
binding did not affect its interaction with cancer cells (Fig. 3B). In
addition, the neutralizing antibody GRE1 did not inhibit the
binding of gremlin-1 to BMP-2 or BMP-4 (Fig. 3A). Therefore, we
conclude the interaction of gremlin-1 with A549 cells is likely
mediated by a different motif than the motif involved in the
interaction with BMPs.
When A549 cells were incubated with gremlin-1, the cell
morphology became fibroblast-like and cells were scattered
(Fig. 4A). We also found decreased E-cadherin expression when
cells were incubated with gremlin-1 (Fig. 4B, 4C, and 5B). Down-
regulation of E-cadherin is associated with epithelial-mescenchy-
mal transition (EMT) and the suppression of E-cadherin [25] and
EMT are commonly observed in the progression of cancer [26]. In
a scratch wound healing assay, gremlin-1 increased the migration
of A549 cells. Addition of the neutralizing antibody GRE1
Figure 5. Characterization of gremlin-1-transfected A549 cell lines. (A) RT-PCR and western blot analyses indicate gremlin-1 mRNA and
protein are expressed in gremlin-1-A549 cells but not mock-A549 cells. (B) E-cadherin protein expression is reduced in gremlin-1-A549 cells and this
effect is attenuated upon addition of the neutralizing antibody GRE1. (C) Gremlin-1-A549 cells show increased invasiveness in cell invasion assays as
compared to mock-A549 cells. The cells on the underside of the ECM membrane were stained and counted. ***P,0.001, Student’s t test. (D) Gremlin-
1-A549 cells show increased migration compared to mock-A549 cells and this effect is attenuated upon the addition of the neutralizing antibody
GRE1. **P,0.01, ***P,0.001, Student’s t test. (E) Gremlin-1-A549 cells display an increased growth rate compared to mock-A549 cells as determined
by MTS proliferation assay. The neutralizing antibody GRE1 addition blocks this effect. *P,0.05 versus mock-A549, Student’s t test. (F) Gremlin-1-A549
cells injected subcutaneously in nude mice have an increased rate of tumor growth in vivo as compared with injection of mock-A549 cells. Tumor
volume is depicted as the average 6 standard deviation. *P,0.05 versus mock-A549, Student’s t test.
doi:10.1371/journal.pone.0035100.g005
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Furthermore, gremlin-1-A549 cells showed increased invasion
through the ECM-coated membrane. It was previously reported
that transfection of A549 cells with gremlin-1 sensitized the cells to
EMT upon treatment with TGF-b1 [27]. However, induction of
an EMT-like phenotype by gremlin-1 alone has not been reported.
Gremlin-1-A549 cells also showed increased proliferation in vitro
and in vivo (Fig. 5E & 5F). In an In vitro setting, the increased
proliferation rate was reduced upon addition of the GRE1
antibody. Experiments are currently underway to investigate if
gremlin-1 directly influences tumor growth. These data suggest
that the secretion of gremlin-1 may increase cell proliferation and
thus affect tumorigenesis.
Supporting Information
Figure S1 The specificity of the GRE1 antibody. Western
blot analysis (A) and Coomassie staining (B) of the culture
supernatant of HEK293F transfected with gremlin-1 indicates that
GRE1 reacts specifically with gremlin-1. Lanes 1 and 2 were
loaded with culture supernatant of HEK293F cells that were
mock-transfected or transfected with gremlin-1, respectively. The
gremlin-1 protein has post-translational modification sites and
exists in two major forms (glycosylated and unglycosylated) [1].
(TIF)
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